In this newly published study from Mayo Clinic (Apr 2022), patients with obstructive sleep apnea (OSA) and comorbid cardiovascular disease (CVD) who were effectively treated for OSA were nearly $4,500 less expensive than those not adherent with their OSA treatment:

Click thumbnail to view PDF →

EnsoData, the leader in Al/ML for sleep, combines our technology with best-in-class care service partners to help payers and at-risk providers dramatically improve sleep apnea treatment success.

Did you know?

Sleep apnea is prevalent in 3 of 4 people with healthcare’s most common and expensive conditions. Untreated sleep apnea diminishes the impact of ANY intervention to improve outcomes for this population.

Sleep Apnea Prevalence in Common Comorbidities
  1. Johnson KG and Johnson DC. J Clin Sleep Med 2010
  2. Einhorn D et al Endocr Pract 2007
  3. O’Keefe T and Patterson EJ. Obes Surg 2004
  4. Bitter T et al. Dtsch Aztebl Int. 2009
  5. Oldenburg O et al. Eur J Heart Fail 2007
  6. Logan AG et al. Journal of Hypertension 2001
© Copyright 2023 EnsoData Inc. All rights reserved.